Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

5th Closed Expert Meeting of the Editorial Board

26th August 2016, Rome, Italy

Optimal treatment in children with FH urgently needed!

Optimal treatment in children with FH urgently needed!

Familial hypercholesterolaemia (FH, inherited high cholesterol) is the most common inherited cause of premature coronary heart disease, affecting about 1 in 200-250 people (1). This means that worldwide, one baby is born with FH every minute. Therefore, diagnosing children with FH earlier, so that lifestyle…

read more »
Insights from Brazil: Raul Santos, InCor-University of Sao Paulo

Insights from Brazil: Raul Santos, InCor-University of Sao Paulo

The Healthcare Perspective in South America

read more »
Outcomes data are critical

Outcomes data are critical

The Healthcare System Perspective in Europe: Francois Mach, University of Geneva, Switzerland

read more »
Many key barriers are amenable to change; new strategies are needed

Many key barriers are amenable to change; new strategies are needed

General considerations: David L. Hare, University of Melbourne Australia

read more »
What prevents high risk patients gaining access to treatment with PCSK9 inhibitors?

What prevents high risk patients gaining access to treatment with PCSK9 inhibitors?

Roundtable discussion from the Fifth Closed Expert Meeting of PCSK9 Forum focused on identifying barriers to access to treatment with PCSK9 monoclonal antibody therapy, from both the patient and healthcare system perspectives. Access in developing countries is especially problematic, according to insights from South America….

read more »
PCSK9 inhibitors: Who and when to treat?

PCSK9 inhibitors: Who and when to treat?

Professor Tony Wierzbicki (Guy’s & St Thomas’ Hospitals, London, UK) discusses considerations for the use of PCSK9 inhibitors from a policy maker perspective (NICE, National Institute for Health and Care Excellence in the UK). He raises issues about the data for each high risk patient…

read more »
Current status of IVUS studies of plaque burden: what next with GLAGOV?

Current status of IVUS studies of plaque burden: what next with GLAGOV?

Over the last decade, the use of serial intravascular ultrasound (IVUS) imaging has been critical for defining the relationship between achieved LDL cholesterol levels and atherosclerotic plaque burden. In this overview, Professor Steve Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia) discusses the…

read more »